Arthneeti

Beta Drugs Q2 FY27 Share Price & Earnings Call Analysis

₹1,849.70-6.43% today
Market cap
₹2,050 Cr
P/E
44.99
ROE
18.78%
PEG
4.27
Price to sales
5.01
Debt to equity
0.60
52W high / low
₹2,668 / ₹1,030
Sales growth (5Y)
27.08%
EBITDA margin
20.32%
Net profit margin
10.78%
Promoter holding
58.91%
Sales (last year)
₹410 Cr

Beta Drugs Ltd is engaged in manufacturing of a wide range of oncology (anti-cancer) drugs in India. It has operations in the domestic and export markets.[1]

Guidance scorecard · Q2 FY27 call

What Beta Drugs Ltd's management guided
and where it ranks in Pharmaceuticals & Biotechnology

#13of 83 in
Pharmaceuticals & Biotechnology
Revenue20–40%MarginsUp 0–2%CapexPlannedFundraisingWhat management saidOrder bookRising

RevenueQ2 FY27 call

20–40%
  • Beta Drugs aims for overall branded business growth of 20% to 25% over the medium term.
  • Nivian acquisition (66% stake) expected to deliver faster growth, targeting 30%-35% CAGR over next 2-3 years.
  • Exports are projected to have exponential growth, driven by product approvals and tender commercialization; a CAGR of around 30% is envisaged.
  • FY27 export revenue guidance is INR 90-100 crores, with a medium-term target of INR 300 crores in next 3-4 years.
  • CMO business guided for INR 180-190 crores revenues in FY27, supported by new products including NDDS with higher margins.
  • Beta targets INR 1,000 crores revenue by FY30, fueled by branded, export, CMO/API, and Nivian segments.

2 more points from Beta Drugs Ltd's call on revenue

Create a free account to keep reading this call

Full Q2 FY27 analysis

MarginsQ2 FY27 call

Up 0–2%

See what Beta Drugs Ltd said on margins — free account, 30 seconds.

Full Q2 FY27 analysis

CapexQ2 FY27 call

Planned
  • Investment of INR15 crores and INR17 crores has been made in the API/intermediate plant, which will go live by January 2027 after completion of approvals and qualifications.
  • New intermediate plant set up to manufacture intermediates in India, reducing dependence on imports from China.
  • Acquired land for R&D purposes; disposal pending for another land parcel, expected within 6 months to 1 year.

2 more points from Beta Drugs Ltd's call on capex

Create a free account to keep reading this call

Full Q2 FY27 analysis

FundraisingQ2 FY27 call

See what Beta Drugs Ltd said on fundraising — free account, 30 seconds.

Full Q2 FY27 analysis

Order bookQ2 FY27 call

Rising
  • The company has a robust export order pipeline with 872 new registrations in progress over the next 2-3 years.
  • Out of these, approximately 50 registrations are expected to be obtained within the current year.
  • Export sales for H1 '27 were INR43 crores excluding one-time opportunity sales last year of INR25 crores.
  • The CDMO (Contract Development and Manufacturing Organization) business has a strong repeat customer base with no partner lost in 15 years.
  • The CMO business is guided at INR180-190 crores for FY27 with consistent growth expected.

2 more points from Beta Drugs Ltd's call on the order book

Create a free account to keep reading this call

Full Q2 FY27 analysis
Full Pharmaceuticals & Biotechnology ranking

Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.

Potential multibaggers · Q2 FY27

Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Strong growth
    3
See all potential multibaggersWhere does Beta Drugs Ltd rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Pharmaceuticals & Biotechnology companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹556 Cr22.1
240%+Up 0–2%₹215 Cr22.2
340%+Flat₹16,144 Cr—
440%+Flat₹6,072 Cr48.0
540%+Flat₹40 Cr—
620–40%Up 2%+₹50,220 Cr43.8

Sign up free to see every company in the sector ranking and track Beta Drugs Ltd.

Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology ranking

Financials of Beta Drugs Ltd

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Shareholder Pattern

Beta Drugs Ltd

Shareholding breakup across reporting periods.

Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Promoters +66.73%66.73%66.73%66.73%66.73%66.73%66.73%66.73%64.90%64.63%59.10%58.91%
FIIs +0.32%0.32%0.90%1.16%1.15%0.90%0.90%0.90%1.14%1.16%1.02%1.37%
DIIs +0.02%0.06%0.12%0.16%0.17%0.17%0.26%0.29%1.90%2.15%6.23%6.45%
Public +32.92%32.87%32.25%31.95%31.95%32.20%32.11%32.07%32.07%32.06%33.65%33.27%
No. of Shareholders1,9282,1162,3232,5672,8823,0543,1393,1843,6944,7367,35910,145

Financials of Beta Drugs Ltd

Quarterly Results

Quarter-by-quarter operating performance

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales +88941001038794126137
Expenses +70768182707698107
Operating Profit1817202117182730
OPM %21%18%20%21%19%19%22%22%
Other Income +-12332322
Interest23344432
Depreciation34444545
Profit before tax1212161610122226
Tax %25%26%25%26%19%24%25%25%
Net Profit +991212991619
EPS in Rs8.868.9511.5912.118.408.9314.2516.68

Financials of Beta Drugs Ltd

Profit & Loss

Annual income statement trend

Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales +516691116184227296362384444
Expenses +41547391141174236287309352
Operating Profit9121825435360757692
OPM %19%18%20%21%23%23%20%21%20%21%
Other Income +00001112119
Interest113222371513
Depreciation234771010131718
Profit before tax781216344149575470
Tax %1%-2%21%27%28%25%25%26%24%
Net Profit +78912253136424153
EPS in Rs7.438.849.3311.6024.5830.4236.0842.0240.9248.26
Dividend Payout %0%0%0%0%0%0%0%0%0%

Financials of Beta Drugs Ltd

Balance Sheet

Capital structure and asset base

Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital991010101010101011
Reserves2432485983113148187235427
Borrowings +820231721201513814849
Other Liabilities +9222831455582101103170
Total Liabilities5083107118158198254436496656
Fixed Assets +1318444055636589125220
CWIP11503000009
Investments0001110000
Other Assets +35506374102135190347371427
Total Assets5083107118158198254436496656

Financials of Beta Drugs Ltd

Cash Flows

Operating, investing and financing cash movement

Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +1708193023313637
Cash from Investing Activity +-11-21-15-6-22-19-14-36-51
Cash from Financing Activity +5129-8-1-2-7118-8
Net Cash Flow12-925729118-22
Free Cash Flow9-21-71310519-1-16
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit181%1%47%75%69%44%52%48%49%

Financials of Beta Drugs Ltd

Ratios

Working capital efficiency and return ratios

Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days1041391281069010198103113
Inventory Days3710410210087106122127159
Days Payable81143119127123139145152172
Cash Conversion Cycle601001117953687579100
Working Capital Days504056766173807197
ROCE %18%21%22%36%34%33%27%19%

Guidance history

How Beta Drugs Ltd's guidance has moved, call by call

CallRevenueMarginsCapexFundraisingOrder book
Q2 FY27 call →20–40%Up 0–2%Planned—Rising
Q4 FY26 call →20–40%Up 0–2%PlannedPlannedRising
Q2 FY26 call →20–40%FlatPlanned——
Q4 FY25 call →20–40%FlatPlanned——

What management guided on each call, newest first. Not investment advice, and not a forecast of returns.

31out of 100

Momentum score · price trend

31 out of 100 — Cooling

Over the past year its share price has done worse than most of the stocks we track.

PeriodShare price changeBetter than … of 1,910 stocks
Last 12 months−2.4%58%
Last 6 months+39.1%85%
Last 3 months−16.1%26%

The price is 30.7% below its all-time high of ₹2,668.3 (11 Aug 2026). Stocks more than 20% below their peak have their score halved, so 62 became 31.

How we calculate it

“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).

The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Beta Drugs Ltd: 0.4 × 58 + 0.4 × 85 + 0.2 × 26 = 62, halved to 31 because the price is more than 20% below its all-time high.

Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.

Full methodology →

This describes only how the share price has moved up to 29 Oct 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.

Continue your research

What Beta Drugs Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Lincoln Pharmaceuticals Ltd (Q2 FY27)

    2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it

  • Alivus Life Sciences Ltd (Q2 FY27)

    Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest

  • Strides Pharma Science Ltd (Q2 FY27)

    Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation

  • Laurus Labs Ltd (Q2 FY27)

    2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd